Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 20:12:711813.
doi: 10.3389/fphar.2021.711813. eCollection 2021.

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Dominique Berton  1 , Anne Floquet  2 , Willy Lescaut  3 , Gabriel Baron  4 , Marie-Christine Kaminsky  5 , Philippe Toussaint  6 , Rémy Largillier  7 , Aude-Marie Savoye  8 , Jérôme Alexandre  9 , Catherine Delbaldo  10 , Emmanuelle Malaurie  11 , Hugues Barletta  12 , Claire Bosacki  13 , Claire Garnier-Tixidre  14 , Philippe Follana  15 , Hortense Laharie-Mineur  16 , Charles Briac Levache  17 , Bruno Valenza  18 , Agnès Dechartres  19 , Delphine Mollon-Grange  20 , Frédéric Selle  10
Affiliations

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Dominique Berton et al. Front Pharmacol. .

Abstract

Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB-IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment administration and outcomes in the French real-world setting. Patients and Methods: Eligible patients were aged ≥ 18 years with planned bevacizumab-containing therapy for newly diagnosed ovarian cancer. The primary objective was to assess the safety profile of front-line bevacizumab in routine clinical practice; secondary objectives were to describe patient characteristics, indications/contraindications for bevacizumab, treatment regimens and co-medications, follow-up and monitoring, progression-free survival, and treatment at recurrence. In this non-interventional study, treatment was administered as chosen by the investigator and participation in the trial had no influence on the management of the disease. Results: Of 1,290 patients screened between April 2013 and February 2015, 468 were eligible. Most patients (86%) received bevacizumab 15 mg/kg every 3 weeks or equivalent, typically with carboplatin (99%) and paclitaxel (98%). The median duration of bevacizumab was 12.2 (range 0-28, interquartile range 6.9-14.9) months; 8% of patients discontinued bevacizumab because of toxicity. The most common adverse events were hypertension (38% of patients), fatigue (35%), and bleeding (32%). There were no treatment-related deaths. Most physicians (90%) reported blood pressure measurement immediately before each bevacizumab infusion and almost all (97%) reported monitoring for proteinuria before each bevacizumab infusion. Median progression-free survival was 17.4 (95% CI, 16.4-19.1) months. The 3-year overall survival rate was 62% (95% CI, 58-67%). The most commonly administered chemotherapies at recurrence were carboplatin and pegylated liposomal doxorubicin. Discussion: Clinical outcomes and tolerability with bevacizumab in this real-life setting are consistent with randomized trial results, notwithstanding differences in the treated patient population and treatment schedule. Clinical Trial Registration:ClinicalTrials.gov, Identifier NCT01832415.

Keywords: bevacizumab; monitoring; ovarian cancer; progression-free survival; routine clinical practice.

PubMed Disclaimer

Conflict of interest statement

AF reports honoraria and travel/accommodation/expenses from AstraZeneca, Clovis, and GSK, and non-remunerated activities for MSD and Roche. PT reports honoraria from MSD, Tesaro/GSK, and Pfizer, and advisory/consultancy roles for MSD and Tesaro/GSK. JA reports honoraria from GSK, AstraZeneca, MSD, PharmaMar, and Eisai; travel/accommodation/expenses from Novartis, Janssen, and GSK; and research grant/funding to his institution from Janssen and MSD. CG-T reports honoraria from and advisory/consultancy roles for Pfizer; speaker bureau/expert testimony for AstraZeneca and MSD; travel/accommodation/expenses from MSD, Pfizer, and Mylan; and research grant/funding to her institution from Roche. PF reports honoraria from and advisory/consultancy roles for Novartis, AstraZeneca, GSK, and Clovis, and travel/accommodation/expenses from Novartis, AstraZeneca, and GSK. CBL reports honoraria (paid to his institution) from Roche, Novartis, Isofol, Array Biopharma, AstraZeneca, BMS, and Celgene. FS reports honoraria from Roche, AstraZeneca, Tesaro, Clovis, MSD, PharmaMar, and GlaxoSmithKline; advisory/consultancy role for Roche; speaker bureau/expert testimony for Roche, AstraZeneca, Tesaro, and GlaxoSmithKline; and travel/accommodation/expenses from Roche, AstraZeneca, Tesaro, MSD, and PharmaMar. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Patient flow. More than one reason for not enrolling is possible. A total of 667 “other” reasons were reported in 593 patients.
FIGURE 2
FIGURE 2
Percentage (in descending order) of patients experiencing adverse events (all grades). Verbatim terms recorded under target adverse event categories were as follows: thromboembolic events: phlebitis (n = 8), pulmonary embolism (n = 6), cerebrovascular accident (n = 1), other (n = 12). Gastrointestinal toxicity: subileus (n = 2), gastrointestinal perforation, constipation, abdominal distention, upper abdominal pain, dyspepsia, fistula, enterocutaneous fistula, perineal fistula, umbilical hernia, intestinal occlusion, wound evisceration/stomal complication/fistula/dehiscence/urinoma, gastrointestinal disorders (each n = 1). Cardiac toxicity: hypertension (n = 2), palpitations (n = 2), pulmonary artery hypertension, aortic insufficiency/palpitations/supraventricular extrasystole, acute coronary syndrome, tachycardia, poorly defined (each n = 1). PRES, posterior reversible encephalopathy syndrome.
FIGURE 3
FIGURE 3
Clinical outcomes in the 468 analyzed patients. Kaplan-Meier curves are truncated at 36 months. (A) Progression-free survival (PFS). (B) Overall survival (OS).
See this image and copyright information in PMC

References

    1. Avastin Prescribing Information (2020). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125085s332lbl.pdf (Accessed Mar 24, 2021).
    1. Burger R. A., Brady M. F., Bookman M. A., Fleming G. F., Monk B. J., Huang H., et al. (2011). Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N. Engl. J. Med. 365, 2473–2483. 10.1056/NEJMoa1104390 - DOI - PubMed
    1. de la Motte Rouge T., Ray-Coquard I., You B. (2019). [Medical Treatment in Ovarian Cancers Newly Diagnosed: Article Drafted from the French Guidelines in Oncology Entitled "Initial Management of Patients with Epithelial Ovarian Cancer" Developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the Aegis of CNGOF and Endorsed by INCa]. Gynecol. Obstet. Fertil. Senol 47, 222–237. 10.1016/j.gofs.2019.01.002 - DOI - PubMed
    1. Hall M., Bertelli G., Li L., Green C., Chan S., Yeoh C. C., et al. (2020). Role of Front-Line Bevacizumab in Advanced Ovarian Cancer: the OSCAR Study. Int. J. Gynecol. Cancer 30, 213–220. 10.1136/ijgc-2019-000512 - DOI - PubMed
    1. Institut National du Cancer (INCa) (2021). Tumeurs solides - Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Available at: https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publica... (Accessed Mar 24, 2021).

Associated data